Review Article

Tuberculosis – An overview

Kanthesh M Basalingappa^{1,*}, Pugazhandhi B², Nagalambika P³,
Gopenath T S⁴, Veena Gowda S⁵, Karthikeyan M⁶, Ashok G⁶, S D K Shri Devi⁷

¹Division of Molecular Biology Faculty of Life Sciences, JSS AHER, Mysuru, Karnataka, India

²Melaka Manipal Medical College (Manipal Campus), Manipal Academy of Higher Education, Manipal, Karnataka, India

³Dept. of Microbiology, Faculty of Life Sciences, JSS AHER, Mysuru, Karnataka, India

⁴Dept. of Biotechnology & Bioinformatics, Faculty of Life Sciences, JSS AHER, Mysuru, Karnataka, India

⁵Faculty of Life Sciences, JSS AHER, Mysuru, Karnataka, India

⁶Dept. of Microbiology, Quest International University Perak, Perak Darul Ridzuan, Malaysia

⁷Sri Sarada College for Women (Autonomous), Affiliated to Periyar University, Salem, Tamil Nadu, India

ARTICLE INFO

Article history:

Received 10-05-2021

Accepted 22-05-2021

Available online 30-07-2021

Keywords:

Tuberculosis

Drug-resistant Tuberculosis

Malaysia

ABSTRACT

Tuberculosis (TB) is a chronic infection of *Mycobacterium tuberculosis*. It is spread through the air from person to person and mainly targets the lungs. The tuberculosis epidemic has been complicated by the emergence of drug-resistant TB and HIV-associated TB. In Malaysia, there were an estimated 0.4% of 40,000 TB cases with MDR-TB in 2014. The acquisition of drug resistance in *M. tuberculosis* is mainly depending on the efflux mechanisms which allow the bacteria to tolerate higher levels of a drug. The evolutionary pathway of drug resistance is influenced by epistasis and bacterial fitness. There are a few risk factors that responsible for the occurrence of drug-resistant TB.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Tuberculosis (TB) is caused by the strain *Mycobacterium Tuberculosis* and is known to be one of the human-known diseases which exist for a long time. TB has many forms of manifestation, of which pulmonary TB to be the most common form of manifestation. Besides pulmonary involvement, TB can also affect the central nervous system, bones (Pott's disease), and other systems. Being a multi-system targeting organism, TB will bring out a severe complication to one's health. It's all beginning from aerosol droplets that contain *Mycobacterium Tuberculosis* strains onto the lung alveolar surface. Once get infected, it will trigger the inflammatory cell infiltration where it tries to contain the bacteria in a place, forming a primary Ghon complex where it prevents the spread of the organism to another part of the body. It can either remain latent or

reactive were the primary Ghon complex rupture and give rise to secondary TB. Although it does not produce any forms of a toxin like another organism, *Mycobacterium tuberculosis* virulence is not simple and complex since its structural and physiological features make it virulent. Some of the structural and physiological aspects include the ability to grow intracellularly, detoxification of radicals from oxygen, cord factor, high lipid density in the cell wall, Erp surface-located protein, mycocerosic acid, and adherence such as heparin-binding hemagglutinin (HbhA) are the most probable cause. Proper investigation and management should be done to cure TB patients. The investigation includes identification of acid-fast bacilli using BACTEC System via Ziehl Neelsen stains and culture.

2. Source of Information

For the literature, a total number of 6146 articles related to emerging aspects of tuberculosis were retrieved. Out

* Corresponding author.

E-mail address: kantheshmb@jssuni.edu.in (K. M. Basalingappa).

of these 6146 articles, most of the articles were full-length articles and only a few were abstracts. Additional publications from World Health Organization (WHO) website, Clinical Research Centre (CRC) were also included. The database that used to search for relevant materials were from BioMed Central, PubMed Central, World Health Organization (WHO), the Malaysian Journal of Medical Sciences (MJMS), the Centers for Disease Control and Prevention (CDC) and Ministry of Health of Malaysia (MOH).

3. Characteristics of Mycobacterium Tuberculosis

Tuberculosis is a chronic infection of *Mycobacterium tuberculosis*. It is spread through the air from person to person and mainly targets the lungs of an individual. Most of the infected people have latent TB, only some will develop active TB disease. *Mycobacterium tuberculosis* is a bacterium in the form of a nonmotile rod, also known as Koch's bacillus. It is a slow-growing bacterium that requires aerobes and is categorized as acid-fast bacteria. Middlebrook's medium and Lowenstein-Jensen medium is used to grow *Mycobacterium tuberculosis*. Its cell wall contains peptidoglycan and three major lipid components like mycolic acids, cord factor and wax-D. Mycolic acids are powerful hydrophobic molecules that create a lipid shell and affect the permeability of the cell surface. The cord factor is harmful to mammalian cells and is an inhibitor of PMN migration. In the cell envelope, wax-D is found and also a major component of the Freund's complete adjuvant. Special characteristics such as stain and dye absorption coefficient, tolerance to certain antibiotics, acid and alkaline compound resistance. Killing, resistance by complement deposition to osmotic lysis and resistance to lethal oxidation and survival of macrophage have been provided by high lipid concentrations in the *Mycobacterium tuberculosis* cell wall.¹

4. Epidemiology of Tuberculosis

In 2014, According to the Global TB Survey 2015, 1.5 million people have died from TB, 0.4 million people were HIV positive among these individuals. In 2014, an estimated 9.6 million new TB cases were registered, reflecting a global average of 133 cases per 100,000 population. There were approximately 30,20,000 cases and 4 lakhs 80thousands TB deaths among women. An estimated 10,00,000 childhood TB cases and 140,000 deaths have been reported as well. An approximate 5.4 million cases of TB among men and 890,000 deaths have been reported. In the WHO South-East Asia Region and the WHO Western Pacific Region, the largest number of new cases of TB occurred in 2014, accounting for 58 percent of new cases worldwide. Of all the new activities, five nations, including India, Indonesia, China, Nigeria, and Pakistan, accounted for 54 percent.

Africa, however, had the most extreme burden, with 281 cases per 100,000 inhabitants.²

5. Drug-resistant Tuberculosis

Drug-resistant tuberculosis is widespread, which may jeopardize global TB control and, as found in all countries surveyed, has become a major public health issue. This is due to mismanagement of care and has been transmitted from person to person via the classical tuberculosis transmission model.³ Drug-resistant tuberculosis is divided into multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. The bacteria resistant to isoniazid and rifampin are multidrug-resistant tuberculosis, while the bacteria resistant to fluoroquinolones along with isoniazid and rifampicin are extensively drug-resistant tuberculosis.⁴⁻⁶

6. Epidemiology of Drug-Resistant Tuberculosis

According to the 2015 Global TB Report, there were an estimated 4,80,000 new MDR-TB cases worldwide and 1,90,000 deaths from MDR-TB in 2014. There are also an estimated 300,000 cases of MDR-TB among patients with pulmonary TB. Globally, 123,000 MDR-TB patients have been registered, of whom about 75% live in Europe, India, South Africa, or China. Apart from that, 105 countries have registered XDR-TB. An approximate 9.7 percent of people with MDR-TB have XDR-TB, on average.² In Malaysia, an estimated 0.4 percent of the 40,000 cases of TB with MDR-TB occurred in 2014, based on the TB country profile. Among the confirmed cases of pulmonary TB, there were an estimated 80 cases of MDR-TB.⁷

7. The Emergence of Drug-Resistant Tuberculosis

The global drug-resistant genetic diversity *Mycobacterium tuberculosis* suggests that drug resistance grows in regional hotspots of TB incidence on multiple occasions. As there has been continuous production of *M. tuberculosis*, this has allowed investigating the genetic determinants of this bacterium's drug resistance.⁸⁻¹⁰ The drug resistance acquisition in *M. Tuberculosis* depends primarily on the efflux processes enabling the bacteria to tolerate higher levels of medication. It does not rely on plasmid resistance and horizontal transfer of genes that play a major role in most bacterial pathogens in the selection of drug resistance.⁹ The concurrent selection and accumulation of mutations conferred by bacterial chromosome resistance has become a driving force for multi-antibiotic-resistant strain growth. These mutations interfere mainly with drug-target binding such as RIF-rpoB and FQ-gyrA, compromise prodrugs activation such as INH-katG and PA-824-fgd, or Over-expression of the target is induced by the promoter region, such as INH/ETH of inhA.¹¹⁻¹⁵ Epistasis and bacterial health impact the evolutionary mechanism of

Fig. 1: TB country profile data and graphs

Table 1: Estimated WHO Regional TB statistics for 2014

Region	TB Mortality	HIV Positive TB Mortality	Prevalence	Incidence	Population
Africa	450,000	310,000	3,200,000	2,700,000	963,361,000
Americas	17,000	6,000	350,000	280,000	981,613,000
Eastern Mediterranean	88,000	3,200	1,000,000	7,40,000	635,745,000
Europe	33,000	3,200	440,000	340,000	907,279,000
South East Asia	460,000	62,000	5,400,000	4,000,000	1,906,087,000
Western Pacific	88,000	4,900	2,100,000	1,600,000	1,845,184,000
Global Total	1,100,000	390,000	13,000,000	9,600,000	7,239,269,000

(Source taken from: WHO | Global tuberculosis report 2015 (Rep.). (n.d.). Retrieved from www.who.int/tb/publications/global_report/en/)

Table 2: Statistics for TB in “High Burden” countries 2014

Country	TB Mortality	HIV Positive TB Mortality	Prevalence	Incidence	Population
Afghanistan	14,000	100	110,000	60,000	31,628,000
Bangladesh	81,000	200	640,000	360,000	159,078,000
Brazil	5,300	2,400	110,000	90,000	206,078,000
Cambodia	8,900	800	100,100	60,000	15,328,000
China	38,000	700	1,200,000	930,000	1,369,436,000
DR Congo	52,000	6,300	4,00,000	240,000	74,877,000
Ethiopia	32,000	5,500	190,000	200,000	96,959,000
India	220,000	31,000	2,500,000	2,200,000	1,295,292,000
Indonesia	100,000	22,000	1,600,000	1,000,000	254,455,000
Kenya	9,400	8,100	120,000	110,000	44,864,000
Mozambique	18,000	37,000	150,000	150,000	27,216,000
Myanmar	28,000	4,100	240,000	200,000	53,437,000
Nigeria	170,000	78,000	590,000	570,000	177,476,000
Pakistan	48,000	1,300	630,000	500,000	185,044,000
Philippines	10,000	100	410,000	290,000	99,139,000
Russian Federation	16,000	1,100	160,000	120,000	143,429,000
South Africa	24,000	72,000	380,000	450,000	53,969,000
Thailand	7,400	4,500	160,000	120,000	67,726,000
UR Tanzania	30,000	28,000	270,000	170,000	51,823,000
Uganda	4,500	6,400	60,000	61,000	37,783,000
Viet Nam	17,000	1900	180,000	130,000	92,423,000
Zimbabwe	2,300	5,200	44,000	42,000	15,246,000
Total for High Burden Countries	940,000	320,000	10,000,000	8,000,000	4,552,704,000

(Source taken from: WHO | Global tuberculosis report 2015 (Rep.). (n.d.). Retrieved from www.who.int/tb/publications/global_report/en/)

drug resistance.¹⁶ Epistasis is characterized as a genetic interaction array where one mutation's phenotypic effect determines the existence of one or more mutations, while growth rate, virulence, and transmissibility are a function of bacterial fitness.^{17,18} Most drug-resistance mutations have been shown to bear a fitness expense that typically includes very small fitness defects in resistant strains. As evolution is an ongoing process, resistant mutant fitness is not fixed and clinical strains typically bypass any resistance-imposed fitness costs relative to laboratory strains carrying the same mutation of drug resistance.¹⁹ It is also proven that *M. tuberculosis* have the capacity to induce disease and develop drug resistance strains from various lineages vary.²⁰ The

HN878 strains within Lineage 2, that is the East Asian lineage which includes the Beijing family of strains, are more mutable as compared to CDC1551 strains within Lineage 4, which is the Euro-American lineage, as they have polymorphisms in DNA replication, recombination, and repair genes.^{21,22} The approaches such as whole-genome sequencing, phylogeny, molecular epidemiology, and mutation frequency analyses have been used to counter drug-resistant evolution *M. tuberculosis*.^{23–25}

8. Conclusion

In summary, since tuberculosis remains a significant public health concern, modification of the global strategy to the unique TB treatment and prevention issues is important. It is critical for planning and vital services within a country to ensure political engagement, support, and stewardship. The implementation of a national strategic plan for the elimination of tuberculosis, integrated in national strategies for the health and social sector, and transparency for its execution should be ensured by the enhancement of central coordination under government stewardship by the setting up a national policy committee on TB. A patient-centered approach to care and service that is compassionate and sensitive to patients' needs and based on clear ethical principles is critical. Consideration should be provided to tailored training and TB awareness-raising events for medical and social care workers in touch with high-risk groups. Social initiatives need to reach beyond people already ill with TB and, through a "health-in-all-policies" approach, often focus on people and populations at risk. Without any financial burden, country-to-country cooperation and national legislation can ensure the functionality and accessibility of TB services for all migrants. In addition, it is necessary to screen for active LTBI TB in TB contacts and selected high-risk groups, and to provide adequate treatment. In short, through bilateral and multinational mechanisms, each country should support the implementation of all aspects of the global tuberculosis strategy, as the promotion of global tuberculosis advocacy could provide the visibility needed for sustained efforts to eradicate tuberculosis.

9. Abbreviations

Tuberculosis (TB); World Health Organisation (WHO); Clinical Research Centre (CRC); Multidrug-resistant TB (MDR-TB); Latent tuberculosis infection (LTBI); Extensively drug-resistant TB (XDR TB); Isoniazid (INH) susceptibility (katG and inhA); Rifampicin (rif); Fluoroquinolone (FQ).

10. Source of Funding

No targeted funding reported.

11. Availability of Data and Materials

All data and materials are presented with this manuscript. No additional materials are available.

12. Competing Interests

Authors declare no competing interest.

Acknowledgements

The KMC Manipal Health Sciences Library, Manipal Academy of Higher Education, Madhav Nagar, Manipal,

Karnataka 576104.

References

1. Tuberculosis. (n.d.). Retrieved June 24, 2016, from. Available from: <http://textbookofbacteriology.net/tuberculosis.html>.
2. WHO | Global tuberculosis report 2015 (Rep.). (n.d.). Retrieved from . Available from: www.who.int/tb/publications/global_report/en/.
3. Adhvaryu M, Vakharia B. Drug-resistant tuberculosis: emerging treatment options. *Clin Pharmacol*. 2011;3:51–67. doi:10.2147/cpaa.s11597.
4. Shah NS, Wright A, Drobniewski F. Extreme drug-resistance in tuberculosis ('XDR-TB'): a global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. *Int J Tuberc Lung Dis*. 2005;9(1):S77.
5. Centers for Disease Control and Prevention. The emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide. *Morb Mortal Wkly Rep*. 2006;55:301–5.
6. Migliori GB, Lodenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? *Eur Respir J*. 2007;29(3):423–7. doi:10.1183/09031936.00001307.
7. TB country profile (Rep.). (n.d.). Available from: <https://extranet.who.int/.../Reports>.
8. Li J, Gao X, Luo T, Wu J, Sun G, Liu Q. Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. *Emerg Microbiol Infect*. 2014;3:e19.
9. Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. *Clin Microbiol Infect*. 2011;17(6):815–20. doi:10.1111/j.1469-0691.2011.03556.x.
10. Gillespie SH. Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective. *Antimicrob Agents Chemother*. 2002;46(2):267–74. doi:10.1128/aac.46.2.267-274.2002.
11. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A. Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase. *Cell*. 2001;104(6):901–12. doi:10.1016/s0092-8674(01)00286-0.
12. Barnard FM, Maxwell A. Interaction between DNA Gyrase and Quinolones: Effects of Alanine Mutations at GyrA Subunit Residues Ser 83 and Asp 87. *Antimicrob Agents Chemother*. 2001;45(7):1994–2000. doi:10.1128/aac.45.7.1994-2000.2001.
13. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. *Mol Microbiol*. 1996;22(3):583–92. doi:10.1046/j.1365-2958.1996.00133.x.
14. Stover CK, Warrenner P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature*. 2000;405(6789):962–6. doi:10.1038/35016103.
15. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. *Int J Tuberc Lung Dis*. 2009;13:1320–30.
16. Weinreich DM. Darwinian Evolution Can Follow Only Very Few Mutational Paths to Fitter Proteins. *Science*. 2006;312(5770):111–4. doi:10.1126/science.1123539.
17. Müller B, Borrell S, Rose G, n Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. *Trends Genet*. 2013;29(3):160–9. doi:10.1016/j.tig.2012.11.005.
18. Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, et al. Effect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2012;56(6):3047–53. doi:10.1128/aac.06460-11.
19. Gagneux S. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis. *Science*. 2006;312(5782):1944–6. doi:10.1126/science.1124410.
20. Johnson R. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. *Int J Tuberc Lung Dis*.

- 2010;14:119–121.
21. Taype CA, Agapito JC, Accinelli RA, Espinoza JR, Godreuil S, Goodman SJ, et al. Genetic diversity, population structure and drug resistance of *Mycobacterium tuberculosis* in Peru. *Infect Genet Evol.* 2012;12(3):577–85. doi:10.1016/j.meegid.2012.02.002.
 22. Mestre O. Phylogeny of *Mycobacterium tuberculosis* Beijing strains constructed from polymorphisms in genes involved in DNA replication, recombination, and repair. *PLoS ONE.* 2011;6(1):e16020. doi:10.1371/journal.pone.0016020.
 23. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC. Genomic analysis identifies targets of convergent positive selection in drug-resistant *Mycobacterium tuberculosis*. *Nat Genet.* 2013;45:1183–9.
 24. Lanzas F, Karakousis PC, Sacchettini JC, Ioerger TR. Multidrug-resistant tuberculosis in Panama is driven by clonal expansion of a multidrug-resistant *Mycobacterium tuberculosis* strain related to the KZN extensively drug-resistant *M. tuberculosis* strain from South Africa. *J Clin Microbiol.* 2013;51:3277–85.
 25. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T. Genome sequencing of 161 *Mycobacterium tuberculosis* isolates from China identifies genes and intergenic regions associated with drug resistance. *Nat Genet.* 2013;45:1255–60.

Author biography

Kanthesh M Basalingappa, Assistant Professor <https://orcid.org/0000-0002-6970-4546>

Pugazhandhi B, PhD Research Scholar <https://orcid.org/0000-0002-6631-8404>

Nagalambika P, Assistant Professor <https://orcid.org/0000-0002-2957-0176>

Gopenath T S, Associate Professor <https://orcid.org/0000-0002-6946-8248>

Veena Gowda S, Scholar

Karthikeyan M, Assistant Professor <https://orcid.org/0000-0002-1820-5720>

Ashok G, Assistant Professor <https://orcid.org/0000-0001-7285-2710>

S D K Shri Devi, Assistant Professor <https://orcid.org/0000-0002-0027-8008>

Cite this article: Basalingappa KM, Pugazhandhi B, Nagalambika P, Gopenath T S, Gowda S V, Karthikeyan M, Ashok G, Devi SDKS. Tuberculosis – An overview. *Indian J Microbiol Res* 2021;8(2):96-101.